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Abstract: Combined direct antineoplastic activity and the long-lasting immunological effects of
allogeneic hematopoietic cell transplant (HCT) can cure many hematological malignancies, but
broad adoption requires non-relapse mortality (NRM) rates and graft-versus-host disease (GVHD)
control. Recently, posttransplant cyclophosphamide (PTCy) given after a bone marrow transplant
significantly reduced GVHD-incidence, while PTCy given with tacrolimus/mofetil mycophenolate
(T/MMF) showed activity following allogeneic peripheral blood stem cell transplantation (alloPB-
SCT). Here, we report the experience of a larger cohort (85 consecutive patients) and expanded
follow-up period (03/2011–12/2019) with high-risk hematological malignancies who received alloPB-
SCT from Human-Leukocyte-Antigens HLA-matched unrelated/related donors. GVHD-prophylaxis
was PTCy 50 mg/kg (days+3 and +4) combined with T/MMF (day+5 forward). All patients stopped
MMF on day+28 with day+110 = median tacrolimus discontinuation. Cumulative incidences were
12% for acute and 7% for chronic GVHD- and no GVHD-attributed deaths. For surviving patients, the
12, 24, and 36-month probabilities of being off immunosuppression were 92, 96, and 96%, respectively.
After a 36-month median follow-up, NRM was 4%; median event-free survival (EFS) and overall
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survival (OS) had yet to occur. One- and two-year chronic GVHD-EFS results were 57% (95% CI,
46–68%) and 53% (95% CI, 45–61%), respectively, with limited late infections and long-term organ
toxicities. Disease relapse caused the most treatment failures (38% at 2 years), but low transplant
toxicity allowed many patients (14/37, 38%) to receive donor lymphocyte infusions as a post-relapse
strategy. We confirmed that PTCy+T/MMF treatment effectively prevented acute and chronic GVHD
and limited NRM to unprecedented low rates without loss of disease control efficacy in an expanded
patient cohort. This trial is registered at U.S. National Library of Medicine as #NCT02300571.
Keywords: allogeneic hematopoietic cell transplantation; graft-versus-host disease; post-transplant
cyclophosphamide; immunosuppression modulation; long term outcomes
1. Introduction
In recent years, extraordinary advances have been made in therapeutics for many
hematological malignancies; however, allogeneic hematopoietic cell transplant (HCT)
represents the only potentially curative and globally affordable treatment for most of
them [1–7].
To allow the widespread use of HCT, issues of transplant toxicity and disease relapse
require immediate address [2,3,5–7]. The key to both of these issues appears to be graft-
versus-host disease (GVHD). As the principal cause of death in allogeneic HCT, GVHD
prevention or treatment requires immunosuppression, which negatively impacts relapse
risk and morbidity [8–10]. Given these facts, all avenues to govern GVHD must be pursued.
As of a few years ago, HCT has relied on a combination of calcineurin-inhibitor
(CNI) plus short course methotrexate (MTX) for GVHD prophylaxis [11,12]. The pair
have proven less than fully effective; up to 80% of patients develop GVHD, nearly 30%
die from immune-related complications, and many long-term survivors deal with severe
forms of chronic-GVHD [8]. The effectiveness of the combination was partially increased
at the beginning of the century through the addition of antithymocyte or antilymphocyte
globulins (ATG/ATLG) [13–16].
Based on the results of previous seminal studies demonstrating that cyclophos-
phamide may target early-proliferating alloreactive T-cells involved in GVHD onset, in
2002, a novel prevention strategy of cyclophosphamide (PTCy) given after bone marrow
graft was successfully used as a single-agent GVHD prophylaxis in the haploidentical HCT
setting [17,18]. This approach quickly extended to matched related and unrelated donors,
and achieved high success in both acute and chronic GVHD control [19,20]. However,
preliminary results were limited by graft source, as peripheral blood stem cells (PBSC)—not
bone marrow cells—are the worldwide preferred donor source in allo-HCT [6,21]. Using
PBSC as a graft—in addition to being the preferred donor option—offers many clinical
advantages, e.g., faster engraftment, lower infection risk, and the hope of a more sustained
graft-versus-tumor effect. Initial attempts to use PTCy as a sole GVHD prophylaxis after
PBSC, however, resulted in a high incidence of GVHD and non-relapse mortality (NRM).
Therefore, many groups started evaluating the combination of PTCy with other immuno-
suppressive agents [22–26]. Tacrolimus/mycophenolate-mofetil (T/MMF)—combining
immunosuppression with an immunomodulant effect—was explored in this setting. The
revealed results were promising [12,24,26,27].
In light of this, we presented data in 2016 on the first 35 patients we treated with
PTCy and tacrolimus/MMF (T/MMF) as GVHD prophylaxis after allo-PBSC-transplant
(PBSCT) [26]. The present study updates those published results for 85 patients followed
for 36 months, with a focus on immunosuppressive modulation, long-term control of
GVHD and late complications, and patient outcomes.
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2. Materials and Methods
All patients underwent PBSC-based HCT and were matched for HLA-A, B, C, DRB1,
and DQB1 alleles to either a related or unrelated donor. The following were deemed
acceptable levels of recipient–donor mismatch: an allele–match for HLA-A, B, C, DRB1,
and DQB1; a single allele disparity for HLA-A, B, C, or DRB1 or DQB1; two allele disparities
for HLA-A, B, or C; a single allele disparity for HLA–DRB1; and a single antigen plus
single allele disparity for HLA-A, B, or C. The Supplemental Information sections of
the previous publication detailed clinical eligibility and exclusion criteria. All patients
signed informed consent before study entry. The study (NCT02300571) was originally
conceived by principle investigators as a phase II study; however, it was approved by
the Ethics Committee as an observational/interventional study. Our primary objective
was to determine the capability of the drug combination to control both acute GVHD
(aGVHD) and chronic GVHD (cGVHD), based on cumulative incidence. Secondarily,
we sought to measure several key indicators of drug combination success: non-relapse
mortality (NRM), infections, overall survival (OS), event-free survival (EFS), cGVHD-EFS,
long-term toxicity, and relapse rate. Acute GVHD was diagnosed based on standard
criteria, whereas cGVHD was determined by both traditional and NIH criteria [28–30].
To account for disease status, stage, and cytogenetic heterogeneity across patients, we
also assessed patients using the refined disease risk index [31]. A post hoc analysis based
on total immunosuppressive burden associated with the transplantation platform was
performed. The analysis considered all posttransplant GVHD control systemic treatments:
GVHD or engraftment syndrome, GVHD after donor lymphocyte infusion (DLI) or second
alloPBSCT, and GVHD prophylaxis for second alloPBSCT. Aside from this list, death
remained the only other immunosuppression risk. Each immunosuppressive agent had
the potential to be used at any point throughout the initial and last day of treatment before
permanent discontinuation. By exception, when treatment gaps exceeded three months,
the discontinuous block durations were summed. Topical agents and budesonide were not
included in these analyses. Competing risks for GVHD were graft failure, relapse, DLI,
and death.
2.1. Conditioning Regimen, Postgraft Immunosuppression, and Supportive Care
Conditioning regimens are reported in Table 1. On day+3 and +4 after transplant, im-
munosuppression began with intravenous administration of cyclophosphamide
(50 mg/kg/day). On day+5 and forward, twice-daily doses of tacrolimus (0.06 mg/kg,
targeting trough blood levels of about 5 ng/mL) and thrice-daily doses of MMF (15 mg/kg)
were started and provided until day+28, at which point MMF was discontinued. On
day+84, a tacrolimus taper was begun. On day+5, a daily G-CSF (5 mcg/kg) was started
and continued until the absolute neutrophil count (ANC) >1.0 × 109/L for three con-
secutive days. As described in the previous publication, patients received prophylaxis
for bacterial, fungal, and viral infections, and for Pneumocystis jirovecii. In cases of fever
(>38.5 ◦C), blood and urine cultures were collected and wide-spectrum antibiotic intra-
venous therapy (i.e., piperacillin/tazobactam at 4.5 g q8 h i.v. and vancomycin at 500 mg
q6 h i.v.) was started until pathogens were identified or clinical control achieved. Diag-
nostic and invasive procedures were performed as described in the first report. Standard
cytomegalovirus (CMV) monitoring by polymerase-chain-reaction (PCR) was begun on
day+10 and continued weekly until day+365 after transplant. Thereafter, monitoring
continued according to patients’ follow-up schedule. Treatment with ganciclovir or val-
ganciclovir began when the number of CMV DNA copies rose above 100/mL (unrelated
donors) or 500/mL (related donors) for two consecutive measurements, or after a viral
load change of >0.5 log IU/mL in peripheral blood plasma. Biweekly plasma samples
were taken to detect the Epstein–Barr virus (EBV) up to one year from transplant and then
whenever was clinically indicated.
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Table 1. Patient and Donor Characteristics. AML: acute myeloid leukemia; ALL: acute lymphoblas-
tic leukemia; MDS: myelodisplastic syndrome; BMT: bone marrow transplantation; CR: complete
response; MDR: minimal residual disease; TBI: total body irradiation; MMF: mofetil mycopheno-
late; CMV (Cytomegalovirus); D (donor); R (recipient). Disease risk corresponding to Center for
International Blood and Marrow Transplant Research CIBMTR classification. * Two patients had
an antigen disparity at DQA1; Cyclophosphamide was also given before alloPBSCT at 14.5 mg/kg
on two consecutive days. ◦ Cyclophosphamide was also given before PBSCT at 10 mg/kg on two
consecutive days. CD 34+ cell doses of cell were available for all patients; CD3+ doses only for 89%
of patients.
Patients’ and Donors’ Characteristics Total (N = 85)









Relapsed AML 8 (25%)
ALL 14 (16%)
ALL 6 (43%)
Relapsed ALL 8 (57%)
Non-Hodgkin Lymphoma 17 (20%)
Multiple Myeloma 12 (14%)
MDS 4 (5%)
Hodgkin Lymphoma 3 (4%)
Aplastic Anemia 1 (1%)
Myelofibrosis 1 (1%)
Disease status at Transplant
1◦ CR 40 (47%)
>1◦ CR 22 (26%)
Active disease 23 (27%)
CIBMTR risk group




Not applicable 1 (1%)
Source of stem cell














8 */10 15 (18%)
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Table 1. Cont.
Patients’ and Donors’ Characteristics Total (N = 85)
CMV serology
CMV D−R− 2 (2%)
CMV D+R− 31 (37%)
CMV D−R+ 2 (2%)
CMV D+R+ 50 (59%)
Conditioning regimen
Busulfan + Cyclophosphamide 25 (30%)
Thiotepa + Treosulfan 11 (13%)
Fludarabine + Treosulfan + Thiotepa 7 (8%)
Treosulfan + Fludarabine + Cyclophosphamide 5 (6%)
Treosulfan + Cyclophosphamide 11 (13%)
Melphalan + Cyclophosphamide 5 (6%)
Treosulfan + Cyclophosphamide + TBI 2Gy ◦ 4 (5%)
Melphalan + Cyclophosphamide + TBI 2Gy ◦ 4 (5%)
Busulfane + Fludarabine 5 (6%)
Fludarabine + Melphalan + TBI 2Gy ◦ 3 (2%)
Fludarabine + Thiotepa + Cyclophosphamide 4 (5%)
Cyclophosphamide + ATG + Fludarabine 1 (1%)
Infused cell dose * CD34+ cell × 106/kg,
Median 7 (range 2–15)
CD3+ cell × 108 kg
Median 2.89 (range 1.123–10.372)
Total Nucleated Cells × 108/kg
Median 12.1 (range 6.9–15.739)
2.2. Monitoring after Transplant
Neutrophil engraftment was defined as the first of three consecutive days posttrans-
plant with an Absolute Neutrophil Count ANC of 0.5 × 109/L. Platelet engraftment was
defined as a platelet count of 20 × 109/L with no transfusion during the preceding seven
days. Posttransplant day+28, +56, +90, +180, and +365 donor chimerism was assessed
on circulating myeloid and CD3+ lymphocytes. Chimerism was determined using short
tandem repeat (STR)-fragment length analysis (AmpFlSTR®Identifiler®PCR Amplification
Kit, Applied Biosystems), with full chimerism defined as more than 97% donor cells.
2.3. Long Term Follow-Up
All patients considered stable (disease in control, off immunosuppressive treatment
(IS) and with no signs of GVHD) after HCT were periodically monitored as follow: a
transplant team clinic was scheduled every 30–60 days, cardiac function was evaluated at
day +100 after HCT (with clinical assessment, electrocardiogram, and echocardiogram),
then every 6 months during the first year, and annually thereafter. Pulmonary Function
tests (PFT) were performed at day +100 after HCT and then every 6 months during the
first year thereafter annually. Thyroid function (TSH, FT3 and FT4) was monitored every
90 days after HCT. Dyslipidemia was monitored at day +100 after HCT and then every six
months. During the transplant team clinic, patients were monitored for blood pressure,
liver dysfunction, muscle and joint diseases, diabetes, and oral and eye manifestations.
Oral and ophthalmologist consults were scheduled annually. The onset of cardiomiopathy
with a reduction of ejection fraction (EF) under 50%, as well as valvular or conduction
anomalies were considered cardiac complications. Onset of a new obstructive disorder was
defined as a reduction of forced expiratory volume in 1 s (FEV1)/forced vital capacity ratio
<0.70 (Tiffenau index) in patients with normal Pulmonary function test (PFT). Onset of a
new restrictive disorder was defined as reduction in lung volumes with normal Tiffenau
index in subjects with normal PFT. Worsening of a preexistent lung disorder was defined
as a decrease in pulmonary functions resulting from a previous restrictive or obstructive
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disorder. When TSH was higher than normal limits and FT4 was lower than the inferior
range of normality, it was considered hypothyroidism. Hyperthyroidism was defined as
lower than normal TSH with higher than upper normal limits of FT4. Dyslipidemia was
diagnosed when total cholesterol was higher than 200 mg/dL, triglycerides were higher
than 150 mg/dL or HDL <40 mg/mL [32].
2.4. Statistical Analyses
Measures of OS, EFS, and cGVHD-EFS were estimated using the Kaplan–Meier
method at their respective 95% confidence intervals (CI) [33–35]. A patient death from any
cause constituted an OS event, and a relapse or death from any cause was characterized
as an EFS event. Chronic GVHD-EFS events, defined broadly per NIH criteria, included
any form of cGVHD, relapse, or death. The values for OS, EFS, and cGVHD-EFS were
each calculated as the time elapsed between transplant date and event date/censor date,
or as the time between transplant date and final follow-up date for patients without an
observed event. For patients treated after transplant with DLI, OS and EFS were calculated
from the date of first DLI. Kaplan–Meier estimates of DFS, OS, and cGVHD-DFS were
compared between groups via log rank statistics and the Cox proportional hazards model.
Discontinued immunosuppression time was determined from the date patients ended their
immunosuppression drug tapers without subsequent resumption. NRM encompassed
all deaths that occurred without evidence of relapse. Standard methods were used to
estimate aGVHD and cGVHD rates, relapse or progression, and NRM. Death was treated
as a competing risk for all other endpoints. Relapse was treated as a competing risk for
NRM. Categorical variables were expressed as proportions and continuous variables were
expressed as medians within their respective ranges. Immunosuppressive burden was
evaluated considering both reversible and nonreversible transitions between states. Multi-
state models and the Aalen–Johansen estimator were used to calculate the probability of
being: (1) alive and not on immunosuppression, (2) alive and on immunosuppression; or
(3) dead (absorbing state). A multistate analysis considering nonreversible transition was
also performed to estimate the instantaneous probability of being in one of five states: (1)
alive and on immunosuppression, (2) alive and off the first immunosuppression, (3) alive
and on the second immunosuppression, (4) alive and off subsequent immunosuppression,
or (5) dead [33]. Statistics were performed using IBM-SPSS Statistics v.20, GraphPad-Prism
v.5, STATA V.16, R version 3.6.3.
3. Results
Eighty-five (85) consecutive patients were enrolled and treated at our Transplant
Center between March 2011 and July 2019 (characteristic summary in Table 1). The median
follow-up of surviving patients was 36 months (range, 5–107); the median follow-up for
the entire population was 26 months.
3.1. Engraftment
The median times to neutrophil and platelet recovery were 14 (range, 11–32) and 16
(range, 10–201) days, respectively. Of the 85 patients, 80 (94%) sustained engraftment, 3
(4%) suffered primary graft failure, and 2 (2%) experienced secondary graft failure. Among
the primary graft failures, two patients received a second transplant (1 HLA-haploidentical
donor, 1 autologous donor), and the third patient died from complications of infection.
One of the two (2%) patients with secondary graft failure received a second haploidentical
transplant and the other received a CD34+ boost from the original donor. Only one patient
experienced delayed engraftment. Median lymphocyte counts (lymphocyte × 103/mmol)
were 0.40, 1.23, 1.24, 1.78, and 2.10 at 28, 56, 84, 180, and 365 days after transplant, respec-
tively. On posttransplant day+28, the median donor chimerism for the engrafting patients
was >97%, and in not-relapsing patients, chimerism continued at >97% control over time,
with no patients requiring transfusion support, even one year after transplant. After
transplant, the median time until discharge was 19 (range, 13–174) days. Within the first
J. Clin. Med. 2021, 10, 1173 7 of 19
100 days after transplant, 16 (19%) patients were readmitted for infection or graft failure
and one patient for sinusoidal obstruction syndrome. Across all cases, the complications
were treated and the patients were subsequently discharged (Table 2).
Table 2. Post-transplant data. ◦ Peripheral blood lymphocyte count was available on day 28, 56,
+84, +180, and +365 for all survivor patients. § Chimerism on peripheral blood was available for
all patients alive without disease relapse. † Toxicities were graded according to standard National
Cancer Institute Common Terminology Criteria for Adverse Events version 4.0. ‡ Hemorrhagic
cystitis and cerebral hemorrhage.
Post-Transplant Data (n = 85)
Engraftment median time
Neutrophils engraftment > 0.5 × 109/L 14 days (range 11–32)
Platelets engraftment > 20 × 109/L 16 days (range 10–201)
Peripheral Blood Lymphocyte count ◦
Day+28 Median (U/µL) 400 (range 10–3640)
Day+56 Median (U/µL) 1200 (range 250–5000)
Day+84 Median (U/µL) 1200 (range 360–5000)
Day+180 Median (U/µL) 1800 (range 400–4900)
Day+365 Median (U/µL) 2100 (range 110–5600)
Chimerism §
Day+28 >97% of patients alive and not relapsed
Day+56 >97% of patients alive and not relapsed
Day+84, +180, +365 >97% of patients alive and not relapsed
CMV reactivation
Incidence 55 (65%)
Median day of reactivation 37 (range 13–330)




E. Coli 5 (36%)
Pseudomonas aeruginosa 4 (29%)
Klebsiella pneumoniae
carbapenemase-producing 3 (21%)
Klebsiella Oxytoca 1 (7%)
Enterococcus Faecium 1 (7%)




Hemorrhage ‡ 6 (7%)
Liver enzymes elevation 5 (6%)




Various bacteria, viruses, and fungal infections affected the study group as described
below. Of the 14 (16%) patients who suffered septicemia during engraftment (days 0 to 26),
Escherichia coli (5 patients), Pseudomonas aeruginosa (4 patients) and Klebsiella pneumoniae
Carbapenemase-producing bacteria (3 patients) were most frequently isolated. Klebsiella
oxytoca and Enterococcus faecium were also isolated in some patients, but less frequently.
During the engraftment phase, 16 (19%) patients experienced fever of unknown origin and
were treated with empirical antibiotic therapy.
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No primary CMV infections were reported, although CMV reactivation (median onset
day+37; range, 13–330) was observed in 55 of 85 patients (65%). Preemptive therapy was
successful in all cases of CMV. No patients developed CMV reactivation after day+365.
No patient developed EBV-related lymphoproliferative disease or an EBV DNA increase
requiring anti-CD20 monoclonal antibody administration. Hemorrhagic cystitis due to
BK virus was seen in 7 of 85 (8%) patients; however, complete resolution of the infection
was achieved in each instance. Two patients suffered HBV reactivation after transplant,
but were successfully treated with antiviral therapy. One patient, who was positive for
HCV RNA pretransplant, underwent transplantation without hepatic toxicity. This patient
began a course of sofosbuvir/velpatasvir on day+100 and complete clearance of the viral
load was achieved within three months.
The incidence of proven new invasive fungal infections was 4% one year after trans-
plant. While no patients died from such infections, two experienced aspergillus pneumonia
and one suffered mucormycosis (Table 2).
3.3. Long-Term Toxicity
Cardiovascular disorders also appeared in a number of patients: 5 (8%) patients
developed hypertension (median onset day+34), 1 (1%) patient’s ejection fraction fell
below 50%, and 1 (1%) patient had a cardiac event during the transplant procedure. After
HCT, 16 (32%) patients exhibited PFT changes: new obstructive disorder (12%), new
restrictive disorder (10%), or worsened preexisting PFT alteration (10%). Several endocrine
system issues emerged in the population: 4 patients (5%) developed thyroid dysfunctions
(3 hypothyroidism, 1 hyperthyroidism); 7 patients (15%) became dyslipidemic; 2 (3%)
patients emerged with diabetes (Type II) (Table 3). One patient developed oral squamous
carcinoma, and two patients developed anterior segment ocular complications (cataracts)
that were successfully treated.
Table 3. Long Term Toxicities. PFT = Pulmonary Function Test; ◦ data were available for 51 patients;
x Data were available for 77 patients; a Data were available for 47 patients; b Data were available for
76 patients; c Data were available for 63 patients; d Data were available for 80 patients, defined as
ejection fraction < 50%.
Long Term Toxicities (All Data Reflect Median Follow Up of 36 Months)
Modification of PFT ◦:
Global Incidence 16 (32%)
New obstructive disorder 6 (12%)
New restrictive disorder 5 (10%)
Worsening of a preexistent disorder 5 (10%)
Emergence of Thyroid disfunction x 4 (5%)
Hypothyroidism 3 (4%)
Hyperthyroidism 1 (1%)
Emergence of Dyslipidemia a
Global incidence 7 (15%)
Emergence of Diabetes b
Global incidence 2 (3%)
Cardiovascular disorders
Emergence of Hypertension c
Global incidence 5 (8%)
Emergence of Hypokinetic Cardiomyopathy d
Global incidence 1 (1%)
No patients developed skeletal complications and no patients developed muscle or
joint diseases.
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3.4. GVHD
All patients were off MMF on day+28, and the median day of tacrolimus discontinua-
tion was +110 (range, 50–333). Immunosuppression had to be restarted for 4 (5%) patients
absent disease progression.
The cumulative incidence across all aGVHD grades was 12% (95% CI; range, 5–19%).
Across aGVHD grades II to III, it was 6% (95% CI; 1 to 11%). There were no grade IV cases
of aGVHD. The median onset of aGVHD was +52 days (range, 22–99) with no cases of
late-onset aGVHD (Figure 1A). All patients with aGVHD were treated with glucocorticoids,








Figure 1. Transplant-related complications. (A) Cumulative incidence of acute graft-versus-host
disease (aGVHD). (B) Cumulative incidence of chronic graft-versus-host disease (cGVHD). (C)
Non-relapse mortality.
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The cumulative incidence of classical cGVHD was 7% (95% CI; range, 2–13%). Of
6 patients with cGVHD, 2 had limited and 4 had extensive forms. According to NIH-
defined criteria, 5 patients had cGVHD: 3 qualified for mild, 1 for moderate, and 1 for
severe. The cumulative incidence of NIH-defined cGVHD was 6% (95% CI; range, 2–15%).
Overall, the cumulative incidence of patients diagnosed with cGVHD requiring systemic
immunosuppressive treatment at one year was 7% (95% CI; range, 2–13%) (Figure 1B).
Median time of onset of cGVHD was +193 days (range, 140–268).
All patients with cGVHD were treated with glucocorticoids and a secondary immuno-
suppressive (IS) treatment (tacrolimus or methotrexate), with all but one discontinued IS at
a median of +313 days (range, 215–817). No patient died of GVHD.
Multistate modeling was used to assess the longitudinal immunosuppressive burden.
In our cohort of survivors, the probability for surviving patients of being off IS at 12, 24, and
36 months was 92% (75% of total study population), 96% (68% of total study population),
and 96% (65% of total study population), respectively. Throughout the follow-up, the off IS
state was maintained for all but 5% of patients who required IS restart (Figure 2A,B).




Figure 1. Transplant-related complications. (A) Cumulative incidence of acute graft-
versus-host disease (aGVHD). (B) Cumulative incidence of chronic graft-versus-host disease 
(cGVHD). (C) Non-relapse mortality. 
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systemic immunosuppressive treatment at one year was 7% (95% CI; range, 2–13%) 
(Figure 1B). Median time of onset of cGVHD was +193 days (range, 140–268). 
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muno uppressive (IS) treatment (tacrolimus or methotr xate), with all but one discon-
tinued IS at a median of +313 days (range, 215–817). No patient died of GVHD. 
Multistate modeling was used to assess the longitudinal immunosuppressive bur-
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Figure 2. Immunosuppression Burden (A) Reversible multistate modeling the instantaneous prob-
ability of being in 1 of 3 states: (1) alive, off immunosuppression (off immunosuppression, yellow
zone), (2) alive, on immunosuppression (immunosuppression, green zone), or (3) dead (death, orange
zone). All patients begin in state 1 on day +5 after transplant, after receiving cyclophosphamide
50 mg/kg on days +3 and +4. Patients may have reversible transition between states (1) and (2) but
death was an absorbing state. (B) Nonreversible multistate modeling the instantaneous probability
of being in 1 of five states: (1) alive, on immunosuppression (IS), (2) alive, off first IS, (3) alive, on
second IS, (4) alive, off subsequent IS, or (5) Dead.
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3.5. Outcomes
The estimated cumulative incidence of NRM at one year was 4% (95% CI; range, 0–7%)
(Figure 1C). The one-year EFS and OS values for all patients were estimated as 65% (95% CI;
range, 55–75%) and 82% (95% CI; range, 74–90%), respectively. The two-year estimations
were 59% (95% CI; range, 51–67%) and 71% (95% CI; range, 62–80%) (Figure 3A,B), respec-
tively. The entire patient cohort has yet to reach the point at which median EFS and OS
values can be determined. Rates of cGVHD-EFS at 1-year were estimated as 57% (95% CI;
range, 46–68%); at 2-years, 53% (95% CI; range, 45–61%) (Figure 3C). The two-year cumu-
lative incidence of relapse was 38% (95% CI: 26–46%) across all patients, and 30% (95%CI:
18–41%) for patients undergoing HCT in complete response (CR) (Figure 3D). In terms of
risk, there was no difference between patients transplanted from siblings compared to those
transplanted from matched unrelated donors (MUD) (HR 1.67, 95% CI; range 0.82–3.41).
The same holds true for those transplanted from an identical donor compared to those
transplanted from a mismatch (HR 0.79, 95% CI; range 0.40–1.56). Most relapses occurred
within 8 months. Patients who achieved a first or subsequent CR before transplantation had
significantly higher EFS values (73% vs. 43% at 1 year; 69% vs. 32% at 2 years) (Figure 3F)
and OS values (88% vs. 65% at 1 year; 77% vs. 55% at 2 years) (Figure 3E), as compared to
patients who did not achieve CR.
Among acute myeloid leukemia (AML) patients (33), the cumulative incidence of re-
lapse was 46% overall (95% CI; range, 28–63%), with 34% (95% CI; range, 18–54%) for those
transplanted while in phenotypic remission. Among acute lymphoblastic leukemia (ALL)
patients, the cumulative incidence of relapse was 50% (95% CI; range, 23–77%), and 42%
(95% CI; range, 15–72%) for those in phenotypic remission. Among patients transplanted
for lymphoma (17 Non Hodgkin Lymphoma and 3 Hodgkin Lymphoma) the cumulative
incidence of relapse was 16% (95% CI; range, 3–40%), but only 1% (95% CI; range, 0,0–44%)
in those in complete remission. In multiple myeloma (13 patients), incidence of relapse was
75% (95% CI; range, 42–94%); of note, no patients were transplanted in first CR and almost
all patients (9 out of 13) underwent transplants while in stable disease.
Fourteen patients received DLI for disease relapse. Of the 14, 43% (6) were infused
from a matched sibling, while the other 57% (8) were infused from an HLA-MUD. The
median time between transplant and DLI was 10 months (range, 3–89). The median
number of DLI infusions per patient was three (range, 1–13). Seven (50%) patients received
systemic disease-specific therapy along with the courses of DLI, while 2 (14%) patients
received radiotherapy to focal lesions. Another 2 patients received DLI associated with
brentuximab-bendamustine or blinatumomab. Median follow-up after DLI for all patients
was 14.7 months (Table 4). The overall response rate (ORR) was 57%, (43CR% and 14PR%)
but in a further 3 patients (21%), disease control was achieved. After DLI treatment,
the incidence of aGVHD (grades I–II) was 31% with no grade III–IV cases. Only 1 (7%)
patient developed cGVHD. All patients with GVHD received a short course of systemic
immunosuppression treatment. Across all patients who received DLI, none died from an
adverse DLI event. The estimated rates of 1-year EFS and 1-year OS from the first DLI were
52% (95% CI; range 26–78%) and 71% (95% CI; range, 47–95%), respectively.
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Table 4. Donor Lymphocyte infusions indications and outcomes.
DLI (n = 14 Patients) *
Indication for treatment
disease relapse 14 (100%)
Source of DLI
matched sibling 6 (43%)
HLA-matched unrelated donors 8 (57%)
Median time between transplant and DLI
Median number of DLI infusions = 3
10 months (range 3–89)
3 months (range 1–13)
Overall response rate 57%
Disease control rate 78%
Incidence of acute GVHD grade I–II 33%
Incidence of acute GVHD grade III–IV 0%
Estimated 1-year EFS 52% (95% CI, 26–78%)
Estimated 1-year OS 71% (95% CI, 47–95%)
* Median follow-up post- donor lymphocyte infusions (DLI) for all patients was 14.7 months.
4. Discussion
It is likely that the treatment landscape of many hematological malignancies will pro-
foundly change in the coming years due to the introduction of sophisticated cell therapies
like chimeric antigen receptor (CAR) T cells [1,36–40].
Right now, allogeneic HCT remains the only potentially curative approach able
to handle the clonal heterogeneity of the disease and able to be scaled to all eligible
patients [41–43]. Hence, any efforts to improve the procedure’s safety and effectiveness
is highly relevant to the clinical community. This study with more patients and a longer
follow-up period confirmed the extreme benefit offered by combination PTCy/T/MMF
after allogeneic PBSC-HCT in controlling major transplant complications and maintaining
transplant-related mortality below 4%.
These results present several clinical benefits and development opportunities worthy
of consideration. Clinical benefits of the therapy include: low incidences of any GVHD
forms, limited need for steroid therapy or other IS forms, and high proportions of patients
who discontinue IS early and definitely. Here, the cumulative incidence of aGVHD (12%
with no grade IV cases) and cGVHD (7% with no extensive cases), regardless of donor type
or degree of HLA mismatching, compared quite favorably with standard CNI-based pro-
phylaxis, for which aGVHD rates are 60–80%, and cGVHD rates are 30–60% [5,8,11,12,21].
Although promising, new strategies appear to have less-pronounced activity levels. These
strategies include: PTCy after BMT-HCT (39–60% aGVHD and 6–21% cGVHD), ATG-based
regimens (23–56% aGVHD, and 16–31% cGVHD), and T/MMF/Sirolimus regimens (26%
aGVHD and 49% cGVHD) [13–16,18–20,33,44,45].
In the present study, most patients were freed from IS after a median of 4 months. This
condition persisted over the long term to become 92% probable for surviving patients (75%
of the entire patient cohort) at 12 months and 96% probable at 24 and 36 months, respec-
tively (68% and 65%, respectively, of the entire population). In traditional calcineurin-based
regimens, it is uncommon to discontinue IS (20%) and relatively common for other IS forms
(including steroids) to be used for long periods after transplantation. Additionally, in newer
strategies, the burden of IS persists— albeit significantly less pronounced [25,33,46,47]. Af-
ter PTCy-BMT, the cumulative incidence of steroid use at three years ranges between 46&
and 68%; the probability of being alive and free from IS ranges between 48–56%, with
10–20% of patients conditioned with busulfan/fludarabine still on IS at 3 years [33]. In
ATG regimens, grade II–IV aGVHD requires additional IS in one-third of patients, and the
rate of cGVHD at two years is approximately 30%, plateauing between 10 and 30% for
periods beyond two years [48,49]. In MUD transplants, the probability of being alive and
off IS lies between 50% and 55%, regardless of time (12, 24, or 36 months) [49].
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Recently, three studies reported on the activity of the PTCy/T/MMF approach. The
first was a retrospective European Bone Marrow Transplantation (EBMT) study in MUD
HLA-mismatched patients. The second represented the first phase III trial between the
two strategies (PTCy/T/MMF and conventional immunosuppression). The third was a
Blood and Marrow Transplant Clinical Trials Network (BMT/CTN) phase II study in which
PTCy/T/MMF was compared with other two experimental regimens, adopting a cohort
of patients treated with tacrolimus and methotrexate (T/MTX) as control for all the three
experimental arms. Overall, their results demonstrated that PTCy had the best profile for
controlling GVHD and immunosuppression length [50–52]. The present update, with the
most extended follow-up period, augments the data of these three large studies, enriching
them with additional detail on immunosuppression regimen modulation over time—likely
a foundational element for future development of the strategy.
Undoubtedly, another set of benefits that GVHD protection provided was evidenced
by the low incidence rates of late infections (LI) in our patients. A large retrospective
study by the Center for International Blood and Marrow Transplant Research reported that
approximately 21% of the deaths that occur two years post-transplant result from LI. To
date, none of the patients in our study who survived more than 24 months has died of a
cause other than disease relapse [53,54]. This result distinguishes the PTCy strategy from
classical CNI/MTX or CNI/MTX/ATG-ATLG regimens, considering the burden of serious
LI present in both of them even long after the date of transplant [11,12,48,49,55].
Control of GVHD, limited IS duration, and low LI rates all contribute to the low long-
term organ toxicity rates reported here [56–59]. Among our surviving and non-relapsing
patients, the onset of cardiovascular, respiratory, renal, or metabolic disease has been rare.
Indeed, a good proportion of our patients resumed their occupations between 9 and 12
months after transplant (verified by personal communication). This is the first time that
inpatients treated with PTCy have reported a descriptive snapshot regarding late organ
toxicity; while it is not possible to draw a comparison with other studies with PTCy and
a longer follow up is needed, the presented data compares well with those registered in
large registry cohorts [32].
Despite the major clinical achievements described here, disease relapse was the princi-
pal cause of treatment failure with PTCy/T/MMF. Compared to other GVHD prevention
methods, it was not associated with a higher risk of relapse (PTCy-BMT 22–44% ATG based
regimens 11–42%) [13–16,18–20]. The fact that most relapses were concentrated in the first
8 months, however, suggests that the balance between the search for tolerance and trigger
of graft versus tumour has to be better modulated. Two possible strategies may be pursued:
first, in patients affected by a high-risk malignancy, implementing a faster IS taper to be
free from IS at day +60; second, consider the robust and quick immunological tolerance that
PTCy/T/MMF often invokes and insert donor lymphocyte infusions (DLI) as part of the
strategy [60,61]. In this regard, the results and toxicity achieved with DLIs paves the way
for evaluation of their use early after transplant and for consideration of PTCy/T/MMF as
a basis from which to develop more selective forms of adoptive cell therapy.
While it is beyond the scope of this study of GVHD prevention to comment on the
outcomes (OS, EFS), their median values demonstrated a satisfactory temporal trend and
are worth noting. Moreover, GVHD-EFS (53% at 2 years) and NRM (4%) portend potential
activity and safety benefits. They may also be beneficial when considering allo-HCT
for diseases with strong evidence of graft-versus-tumor effects, but for which procedure
toxicity and novel forms of therapy have halted further investigations [62–64].
Last, the present study has methodological and translational limitations that cannot be
ignored, and which preclude definitive conclusions. Notwithstanding, it offers solid data
for future clinical trials and reinforces the philosophical transformation of allogeneic HCT
from chemo/radiotherapy-based approaches to more immunologically-safe platforms for
the cure of hematological malignancies.
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5. Conclusions
The present study provides evidence that PTCy/T/MMF after allo-PBSCT allows a
fast engraftment, reduces GVHD substantially, and releases most patients from IS early
and definitely. Those factors not only positively impact LI and long-term posttransplant
complications, but do not appear to obstruct the onset of a sustained graft-versus-tumor
effect. Post-transplant relapses continue to represent a pitfall of the strategy. The limited
NRM described is noteworthy, and may contribute to continuing explorations of allogeneic
HCT as an effective cell-based therapy for the cure of hematological malignancies.
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